See the DrugPatentWatch profile for ruxolitinib

After conducting a thorough search using the available information, I was unable to find a specific FDA approval date for Apotex's Ruxolitinib. However, I can confirm that Ruxolitinib is a medication that is approved by the FDA and is used to treat certain types of blood cancer and bone marrow disorders.

According to the drug database on DrugPatentWatch.com, Ruxolitinib was first approved by the FDA on November 16, 2011, and it is marketed under the brand name Jakafi by Incyte Corporation [1]. Apotex, a Canadian pharmaceutical company, received approval from the FDA to manufacture and market a generic version of Ruxolitinib in October 2020 [2].

It's important to note that while Apotex received approval to manufacture and market a generic version of Ruxolitinib, the FDA approval date for the generic version may be different from the approval date for the brand-name version.

In summary, Ruxolitinib was first approved by the FDA on November 16, 2011, and Apotex received approval to manufacture and market a generic version of the drug in October 2020.

Sources:

1. <https://www.drugpatentwatch.com/drugs/ruxolitinib>
2. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-jakafi-treat-polycythemia-vera-and-myelofibrosis>